Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A28, 15, and 16 (R456H, P42R, and R377Q)
P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450...
Saved in:
| Published in | Biomolecules & therapeutics Vol. 23; no. 2; pp. 189 - 194 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Korea (South)
The Korean Society of Applied Pharmacology
01.03.2015
한국응용약물학회 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2005-4483 1976-9148 1976-9148 2005-4483 |
| DOI | 10.4062/biomolther.2015.009 |
Cover
| Abstract | P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals. |
|---|---|
| AbstractList | P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals. P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (kcat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (kcat/Km) increased up to 2.5 fold with a slight increase of its Km value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals. P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 1A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ∼ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (k cat) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency (k cat/K m) increased up to 2.5 fold with a slight increase of its K m value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals. P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterizethe functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P4501A2*8, R456H; *15, P42R; *16, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes wereexpressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450holoenzyme with an expression level of ~ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however theexpression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P4501A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers (kcat)in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis,the overall catalytic efficiency (kcat/Km) increased up to 2.5 fold with a slight increase of its Km value. This study indicated that thesubstitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reductionof P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefullyexamined in terms of the metabolism of many clinical drugs and environmental chemicals. KCI Citation Count: 4 |
| Author | Kim, In-Hyeok Lim, Young-Ran Ko, Mi-Jung Park, Hyoung-Goo Han, Songhee Yun, Chul-Ho Kim, Donghak Chun, Young-Jin |
| AuthorAffiliation | 3 School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea 2 College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea 1 Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea |
| AuthorAffiliation_xml | – name: 3 School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea – name: 1 Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea – name: 2 College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea |
| Author_xml | – sequence: 1 givenname: Young-Ran surname: Lim fullname: Lim, Young-Ran organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea – sequence: 2 givenname: In-Hyeok surname: Kim fullname: Kim, In-Hyeok organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea – sequence: 3 givenname: Songhee surname: Han fullname: Han, Songhee organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea – sequence: 4 givenname: Hyoung-Goo surname: Park fullname: Park, Hyoung-Goo organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea – sequence: 5 givenname: Mi-Jung surname: Ko fullname: Ko, Mi-Jung organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea – sequence: 6 givenname: Young-Jin surname: Chun fullname: Chun, Young-Jin organization: College of Pharmacy, Chung-Ang University, Seoul 156-756, Republic of Korea – sequence: 7 givenname: Chul-Ho surname: Yun fullname: Yun, Chul-Ho organization: School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea – sequence: 8 givenname: Donghak surname: Kim fullname: Kim, Donghak organization: Department of Biological Sciences, Konkuk University, Seoul 143-701, Republic of Korea |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25767688$$D View this record in MEDLINE/PubMed https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001965494$$DAccess content in National Research Foundation of Korea (NRF) |
| BookMark | eNqNUk1v1DAUtFAR3RZ-ARLysUibxR8vTnxBWq3oh1QJWApXy_E6XVPH3joJaP99EwJd4IA4Pckz45k39gk6CjFYhF5SsgAi2JvKxSb6bmvTghGaLwiRT9CMykJkkkJ5hGaMkDwDKPkxOmnbr4SIgubiGTpmeSEKUZYzFM_7YDoXg_b4k7sNrnZGB2NxrPFq30WzTbGx-APkBNMlw0vvrXcGf9HJ6dC180eonGOaz7EOG0wFPltDLi5HlK2nwzUvio-vn6OntfatffFznqLP5-9uVpfZ9fuLq9XyOjNApcyMKAUHKziVIrfaABRVreWmqktTA8hCc55ryRmnWhtWV8LwCopNJcpCggV-is6me0Oq1Z1xKmr3Y95GdZfUcn1zpQYjAWSgwkTtw07vv2vv1S65Rqe9okSNVatD1WqsWg1VD7K3k2zXV43dGBu6pA_S0e9PJLjt4P5NAc-BM3qIuEvxvrdtpxrXGuu9Djb2raJCACMlyDHiq9-9Hk1-veNA4BPBpNi2ydb_uYL8S2Vcp8ffMAR2_p_aB1uQwpA |
| CitedBy_id | crossref_primary_10_1016_j_dmpk_2016_09_003 crossref_primary_10_1080_14756366_2023_2187327 crossref_primary_10_1016_j_dmpk_2017_10_004 crossref_primary_10_1021_acsami_4c08329 crossref_primary_10_1016_j_bbrc_2016_11_131 crossref_primary_10_1038_s41598_021_83696_x |
| Cites_doi | 10.1016/S0378-1119(98)00567-8 10.1016/j.abb.2003.11.019 10.1007/s12272-011-1103-2 10.1016/j.taap.2003.11.030 10.5487/TR.2014.30.1.033 10.2133/dmpk.20.24 10.1021/bi000869u 10.1038/clpt.1991.176 10.4062/biomolther.2013.086 10.1124/mi.3.4.194 10.1016/S0021-9258(18)41713-9 10.4062/biomolther.2009.17.2.156 10.1126/science.8342039 10.1248/bpb.35.394 10.1074/jbc.M508171200 10.1074/jbc.M611692200 10.1124/dmd.105.005819 10.1146/annurev.pharmtox.45.120403.100010 |
| ContentType | Journal Article |
| Copyright | Copyright © 2015 The Korean Society of Applied Pharmacology 2015 |
| Copyright_xml | – notice: Copyright © 2015 The Korean Society of Applied Pharmacology 2015 |
| DBID | AAYXX CITATION NPM 7X8 5PM ADTOC UNPAY ACYCR |
| DOI | 10.4062/biomolther.2015.009 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall Korean Citation Index |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 1976-9148 2005-4483 |
| EndPage | 194 |
| ExternalDocumentID | oai_kci_go_kr_ARTI_199640 oai:pubmedcentral.nih.gov:4354321 PMC4354321 25767688 10_4062_biomolther_2015_009 |
| Genre | Journal Article |
| GroupedDBID | --- 23N 5-W 5GY 8JR 9ZL AAYXX ADBBV ADRAZ AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK DU5 EF. F5P HYE HZB JDI KQ8 M48 OK1 PGMZT RPM NPM 7X8 5PM ADTOC UNPAY .UV ACYCR |
| ID | FETCH-LOGICAL-c4199-c68634e631965eac447bfa9dbf8cf4497a335a93231aac2fb6c3b47db68794e43 |
| IEDL.DBID | M48 |
| ISSN | 2005-4483 1976-9148 |
| IngestDate | Tue Nov 21 21:47:39 EST 2023 Sun Oct 26 03:40:24 EDT 2025 Tue Sep 30 16:47:46 EDT 2025 Fri Jul 11 13:22:23 EDT 2025 Thu Apr 03 07:07:18 EDT 2025 Tue Jul 01 04:58:28 EDT 2025 Thu Apr 24 23:10:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Allelic variants Methoxyresorufin Phenacetin P450 1A2 Polymorphism |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4199-c68634e631965eac447bfa9dbf8cf4497a335a93231aac2fb6c3b47db68794e43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 G704-000363.2015.23.2.008 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.4062/biomolther.2015.009 |
| PMID | 25767688 |
| PQID | 1664208490 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | nrf_kci_oai_kci_go_kr_ARTI_199640 unpaywall_primary_10_4062_biomolther_2015_009 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4354321 proquest_miscellaneous_1664208490 pubmed_primary_25767688 crossref_primary_10_4062_biomolther_2015_009 crossref_citationtrail_10_4062_biomolther_2015_009 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2015-03-01 |
| PublicationDateYYYYMMDD | 2015-03-01 |
| PublicationDate_xml | – month: 03 year: 2015 text: 2015-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Korea (South) |
| PublicationPlace_xml | – name: Korea (South) |
| PublicationTitle | Biomolecules & therapeutics |
| PublicationTitleAlternate | Biomol Ther (Seoul) |
| PublicationYear | 2015 |
| Publisher | The Korean Society of Applied Pharmacology 한국응용약물학회 |
| Publisher_xml | – name: The Korean Society of Applied Pharmacology – name: 한국응용약물학회 |
| References | (OOOMB4_2015_v23n2_189_017) 2005; 20 (OOOMB4_2015_v23n2_189_013) 1993; 261 (OOOMB4_2015_v23n2_189_019) 2004; 422 (OOOMB4_2015_v23n2_189_015) 2007; 282 (OOOMB4_2015_v23n2_189_001) 1992; 267 (OOOMB4_2015_v23n2_189_009) 2005; 280 (OOOMB4_2015_v23n2_189_010) 2011; 34 (OOOMB4_2015_v23n2_189_016) 1978; 1 (OOOMB4_2015_v23n2_189_003) 2003; 3 (OOOMB4_2015_v23n2_189_008) 2005; 45 (OOOMB4_2015_v23n2_189_004) 2012; 35 (OOOMB4_2015_v23n2_189_011) 1999; 226 (OOOMB4_2015_v23n2_189_014) 2005; 33 (OOOMB4_2015_v23n2_189_006) 1991; 50 (OOOMB4_2015_v23n2_189_007) 2004; 199 (OOOMB4_2015_v23n2_189_012) 2014; 30 (OOOMB4_2015_v23n2_189_002) 2013; 21 (OOOMB4_2015_v23n2_189_005) 2009; 17 (OOOMB4_2015_v23n2_189_018) 2000; 39 1429608 - J Biol Chem. 1992 Nov 5;267(31):22587-94 16174806 - Drug Metab Dispos. 2005 Dec;33(12):1905-10 16207711 - J Biol Chem. 2005 Dec 2;280(48):40319-27 8342039 - Science. 1993 Aug 6;261(5122):731-6 1934864 - Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):508-19 15364546 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):305-15 15770072 - Drug Metab Pharmacokinet. 2005 Feb;20(1):24-33 24404341 - Biomol Ther (Seoul). 2013 Nov;21(6):487-92 76883 - Lancet. 1978 Apr 29;1(8070):943-4 24795797 - Toxicol Res. 2014 Mar;30(1):33-8 9931507 - Gene. 1999 Jan 21;226(2):327-38 17311915 - J Biol Chem. 2007 May 11;282(19):14348-55 10985777 - Biochemistry. 2000 Sep 19;39(37):11319-29 22382327 - Biol Pharm Bull. 2012;35(3):394-9 14725854 - Arch Biochem Biophys. 2004 Feb 1;422(1):23-30 22139682 - Arch Pharm Res. 2011 Nov;34(11):1799-816 14993447 - Mol Interv. 2003 Jun;3(4):194-204 15822170 - Annu Rev Pharmacol Toxicol. 2005;45:27-49 |
| References_xml | – volume: 226 start-page: 327 year: 1999 ident: OOOMB4_2015_v23n2_189_011 publication-title: Gene doi: 10.1016/S0378-1119(98)00567-8 – volume: 422 start-page: 23 year: 2004 ident: OOOMB4_2015_v23n2_189_019 publication-title: Arch. Biochem. Biophys. doi: 10.1016/j.abb.2003.11.019 – volume: 34 start-page: 1799 year: 2011 ident: OOOMB4_2015_v23n2_189_010 publication-title: Arch. Pharm. Res. doi: 10.1007/s12272-011-1103-2 – volume: 199 start-page: 305 year: 2004 ident: OOOMB4_2015_v23n2_189_007 publication-title: Toxicol. Appl. Pharmacol. doi: 10.1016/j.taap.2003.11.030 – volume: 30 start-page: 33 year: 2014 ident: OOOMB4_2015_v23n2_189_012 publication-title: Toxicol. Res. doi: 10.5487/TR.2014.30.1.033 – volume: 20 start-page: 24 year: 2005 ident: OOOMB4_2015_v23n2_189_017 publication-title: Drug Metab. Pharmacokinet. doi: 10.2133/dmpk.20.24 – volume: 39 start-page: 11319 year: 2000 ident: OOOMB4_2015_v23n2_189_018 publication-title: Biochemistry doi: 10.1021/bi000869u – volume: 50 start-page: 508 year: 1991 ident: OOOMB4_2015_v23n2_189_006 publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.1991.176 – volume: 21 start-page: 487 year: 2013 ident: OOOMB4_2015_v23n2_189_002 publication-title: Biomol. Ther. doi: 10.4062/biomolther.2013.086 – volume: 3 start-page: 194 year: 2003 ident: OOOMB4_2015_v23n2_189_003 publication-title: Mol. Interv. doi: 10.1124/mi.3.4.194 – volume: 267 start-page: 22587 year: 1992 ident: OOOMB4_2015_v23n2_189_001 publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(18)41713-9 – volume: 17 start-page: 156 year: 2009 ident: OOOMB4_2015_v23n2_189_005 publication-title: Biomol. Ther. doi: 10.4062/biomolther.2009.17.2.156 – volume: 261 start-page: 731 year: 1993 ident: OOOMB4_2015_v23n2_189_013 publication-title: Science doi: 10.1126/science.8342039 – volume: 35 start-page: 394 year: 2012 ident: OOOMB4_2015_v23n2_189_004 publication-title: Biol. Pharm. Bull. doi: 10.1248/bpb.35.394 – volume: 280 start-page: 40319 year: 2005 ident: OOOMB4_2015_v23n2_189_009 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M508171200 – volume: 282 start-page: 14348 year: 2007 ident: OOOMB4_2015_v23n2_189_015 publication-title: J. Biol. Chem. doi: 10.1074/jbc.M611692200 – volume: 1 start-page: 943 year: 1978 ident: OOOMB4_2015_v23n2_189_016 publication-title: Lancet – volume: 33 start-page: 1905 year: 2005 ident: OOOMB4_2015_v23n2_189_014 publication-title: Drug Metab. Dispos. doi: 10.1124/dmd.105.005819 – volume: 45 start-page: 27 year: 2005 ident: OOOMB4_2015_v23n2_189_008 publication-title: Annu. Rev. Pharmacol. Toxicol. doi: 10.1146/annurev.pharmtox.45.120403.100010 – reference: 15822170 - Annu Rev Pharmacol Toxicol. 2005;45:27-49 – reference: 76883 - Lancet. 1978 Apr 29;1(8070):943-4 – reference: 17311915 - J Biol Chem. 2007 May 11;282(19):14348-55 – reference: 14725854 - Arch Biochem Biophys. 2004 Feb 1;422(1):23-30 – reference: 15770072 - Drug Metab Pharmacokinet. 2005 Feb;20(1):24-33 – reference: 24795797 - Toxicol Res. 2014 Mar;30(1):33-8 – reference: 22382327 - Biol Pharm Bull. 2012;35(3):394-9 – reference: 8342039 - Science. 1993 Aug 6;261(5122):731-6 – reference: 1429608 - J Biol Chem. 1992 Nov 5;267(31):22587-94 – reference: 15364546 - Toxicol Appl Pharmacol. 2004 Sep 15;199(3):305-15 – reference: 24404341 - Biomol Ther (Seoul). 2013 Nov;21(6):487-92 – reference: 22139682 - Arch Pharm Res. 2011 Nov;34(11):1799-816 – reference: 10985777 - Biochemistry. 2000 Sep 19;39(37):11319-29 – reference: 1934864 - Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):508-19 – reference: 16174806 - Drug Metab Dispos. 2005 Dec;33(12):1905-10 – reference: 14993447 - Mol Interv. 2003 Jun;3(4):194-204 – reference: 16207711 - J Biol Chem. 2005 Dec 2;280(48):40319-27 – reference: 9931507 - Gene. 1999 Jan 21;226(2):327-38 |
| SSID | ssj0067156 |
| Score | 1.9879814 |
| Snippet | P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450... P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450... |
| SourceID | nrf unpaywall pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 189 |
| SubjectTerms | Original 약학 |
| SummonAdditionalLinks | – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdY9wAvMMRXx4eMxANIzUjiixM_VtOqgsQ0CkXjybKdeKsaJVPXahp_PXdJl60aoPGUKL7E8vnOd2dffsfYO5clsQpDG8RCyACEKQKq5hAYwBAoUWBzS4Hil0M5nsLn4-T4GibnxvE9Wpr4I_2DXpfkClEWFm1_qC22LRP0u3tse3p4NPzZHBunErW2KZXVQGtizCFaiKG_fWXDDG1VC_8nD_N2ouT9VXVmLi9MWd6wQqNHbTmj8wa8kJJP5nurpd1zv25DO95hgDvs4doZ5cNWeh6ze0X1hNUjNHXtDiH_NjupKJeIRIPXnu9fLmt3SggH_AiSkEfDmA_Lsihnjv_AqJuSagZdUzbgUTLgpsp5JPn7CXpRY2qNJ-3DiUjTrx-esuno4Pv-OFiXZQgcREoFTmZSQCFJeRNctwFS643Krc-cB1CpESIx6BeKyBgXeyudsJDmVmao_AWIZ6xX1VXxgnEPCQCumUWuUEC8VJGDLPQqynzscyv6LL6aJe3WmOVUOqPUGLsQ__Q1_zTxTyP_-mzQvXTWQnb8m_wtTr-eu5kmqG26ntR6vtAYUHzSlKQNIdJcCYdG9aMzFVMV9epcR1JSggIopHneCkvXKcVyGM1lfZZuiFFHQP1ttlSz0wbiG51YEHHUZ0EncHcZy-5_0r9kD-i2zal7xXrLxap4jU7W0r5Za9dvprUeDA priority: 102 providerName: Unpaywall |
| Title | Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A28, 15, and 16 (R456H, P42R, and R377Q) |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25767688 https://www.proquest.com/docview/1664208490 https://pubmed.ncbi.nlm.nih.gov/PMC4354321 http://doi.org/10.4062/biomolther.2015.009 https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001965494 |
| UnpaywallVersion | submittedVersion |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biomolecules & Therapeutics, 2015, 23(2), , pp.189-194 |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: KQ8 dateStart: 20120101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVERR databaseName: KoreaMed Open Access customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: 5-W dateStart: 20130101 isFulltext: true titleUrlDefault: https://koreamed.org/journals providerName: Korean Association of Medical Journal Editors – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1976-9148 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: RPM dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1976-9148 dateEnd: 20250930 omitProxy: true ssIdentifier: ssj0067156 issn: 1976-9148 databaseCode: M48 dateStart: 20120101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELf28QAvCMRX-ZiMxANIzYjjixM_oWqiKkibRqFoPFm2E2_VomR0raD_PXdNmzExEOIpUnyJFf98vt_ZlzvGXvo8TXQcuyiRUkUgbRlRNYfIArpAqQZXOHIUD4_UaAIfTtKTLbapiroewMsbXTuqJzWZVfs_vi3fosIjf91Hc5S8oR_Vm4r4EoVq0R6J3ma7aKo01XI4hO5YQWViVc5VoA1GLYe8TUP0p5dQomCk41lbluXKam3Xs3ATIf09rvLWor6wy--2qn4xWsO77M6abfJBOz3usa2yvs-aIdqydguQf5qe1hQsRNjzJvCD5bzxZ5TCgB9DGnMxSPigqspq6vkXdKspaqbfNeV9LtI-t3XBheKvxkiTRtSajNubY5llH18_YJPhu88Ho2hddyHyILSOvMqVhFKRdqa4MANkLlhduJD7AKAzK2VqkfhJYa1PglNeOsgKp3LU7hLkQ7ZTN3X5mPEAKQAuimWhcQYEpYWHPA5a5CEJhZM9lmzG1fh1UnKqjVEZdE4IF3OFiyFcDOLSY_3uoYs2J8ffxV8gYObcTw3l0qbraWPOZwY9hveGorAhRpkNnAb1iw5NbF02i0sjlKIIBNAo86iFt-t0Mzt6LLsGfCdA_V1vqadnqxzeyFJBJqLHom6K_Mu3PPnvnp6y2_SSNnzuGduZzxblc-RTc7e30pE9tjs5Oh58_QmY_hvQ |
| linkProvider | Scholars Portal |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwELdY9wAvMMRXx4eMxANIzUjiixM_VtOqgsQ0CkXjybKdeKsaJVPXahp_PXdJl60aoPGUKL7E8vnOd2dffsfYO5clsQpDG8RCyACEKQKq5hAYwBAoUWBzS4Hil0M5nsLn4-T4GibnxvE9Wpr4I_2DXpfkClEWFm1_qC22LRP0u3tse3p4NPzZHBunErW2KZXVQGtizCFaiKG_fWXDDG1VC_8nD_N2ouT9VXVmLi9MWd6wQqNHbTmj8wa8kJJP5nurpd1zv25DO95hgDvs4doZ5cNWeh6ze0X1hNUjNHXtDiH_NjupKJeIRIPXnu9fLmt3SggH_AiSkEfDmA_Lsihnjv_AqJuSagZdUzbgUTLgpsp5JPn7CXpRY2qNJ-3DiUjTrx-esuno4Pv-OFiXZQgcREoFTmZSQCFJeRNctwFS643Krc-cB1CpESIx6BeKyBgXeyudsJDmVmao_AWIZ6xX1VXxgnEPCQCumUWuUEC8VJGDLPQqynzscyv6LL6aJe3WmOVUOqPUGLsQ__Q1_zTxTyP_-mzQvXTWQnb8m_wtTr-eu5kmqG26ntR6vtAYUHzSlKQNIdJcCYdG9aMzFVMV9epcR1JSggIopHneCkvXKcVyGM1lfZZuiFFHQP1ttlSz0wbiG51YEHHUZ0EncHcZy-5_0r9kD-i2zal7xXrLxap4jU7W0r5Za9dvprUeDA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Functional+Significance+of+Cytochrome+P450+1A2+Allelic+Variants%2C+P450+1A28%2C+15%2C+and+16+%28R456H%2C+P42R%2C+and+R377Q%29&rft.jtitle=Biomolecules+%26+therapeutics&rft.au=Lim%2C+Young-Ran&rft.au=Kim%2C+In-Hyeok&rft.au=Han%2C+Songhee&rft.au=Park%2C+Hyoung-Goo&rft.date=2015-03-01&rft.pub=The+Korean+Society+of+Applied+Pharmacology&rft.issn=1976-9148&rft.eissn=2005-4483&rft.volume=23&rft.issue=2&rft.spage=189&rft.epage=194&rft_id=info:doi/10.4062%2Fbiomolther.2015.009&rft_id=info%3Apmid%2F25767688&rft.externalDocID=PMC4354321 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2005-4483&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2005-4483&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2005-4483&client=summon |